Heterogeneity in exposed uninfected individuals.

Lucia Lopalco(Vita-Salute San Raffaele University), Antonio G. Siccardi(San Raffaele University of Rome), Adriano Lazzarin(Vita-Salute San Raffaele University), Claudia Barassi(Vita-Salute San Raffaele University), Flavia Lillo(Vita-Salute San Raffaele University), Samuele E. Burastero(Vita-Salute San Raffaele University), Laura Soldini(Vita-Salute San Raffaele University), Giuseppe Tambussi(San Raffaele University of Rome), Claudia Pastori(Vita-Salute San Raffaele University), A. Beretta(San Raffaele University of Rome), Enzo Boeri(National Cancer Institute), Lucinda Furci(Vita-Salute San Raffaele University)
PubMed
January 27, 1998
Cited by 3

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Control of HIV despite the Discontinuation of Antiretroviral Therapy
|New England Journal of Medicine|1999|328